tetano
Editor, Senior Moderator
Vaccine. 2012 Oct 8. pii: S0264-410X(12)01401-6. doi: 10.1016/j.vaccine.2012.09.069. [Epub ahead of print]
The immunogenicity and safety of a single 0.5mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥6 to <36 months: Data from a randomized, Phase III study.
Esposito S, Marchisio P, Montinaro V, Bianchini S, Weverling GJ, Pariani E, Amendola A, Fabiano V, Pivetti V, Zanetti A, Zuccotti GV.
Source
Pediatric Clinic 1, Department of Pathophysiology and Transplantation, Universit? degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Commenda 9, 20122 Milan, Italy. Electronic address: susanna.esposito@unimi.it.
Abstract
This study evaluated the immunogenicity, safety and tolerability of a single 0.5mL dose of the seasonal virosomal subunit influenza vaccine (Inflexal V, Crucell, Switzerland) in 205 healthy, unprimed children aged at least 6 to <36 months, evaluated at four weeks post-vaccination and seven months from baseline. Of the enrolled children, 102 received one single 0.5mL dose and 103 received the standard two 0.25mL doses given four weeks apart. Both treatments evoked an immune response that satisfied the EMA/CHMP criteria for yearly vaccine licensing for all three vaccine strains. Exploratory analyses revealed no differences between the groups at four weeks post-vaccination. Furthermore, immunogenicity was maintained seven months after the first vaccination after both the 0.5mL and standard two 0.25mL doses. Adverse events were comparable between groups and were as expected according to the safety profile of the vaccine; overall, the vaccine was well tolerated. Our results show that a single 0.5mL dose effectively and safely provided long-term immunogenicity to all three influenza strains in unprimed children aged at least 6 to <36 months.
Copyright ? 2012. Published by Elsevier Ltd.
PMID:
23059357
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23059357
The immunogenicity and safety of a single 0.5mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥6 to <36 months: Data from a randomized, Phase III study.
Esposito S, Marchisio P, Montinaro V, Bianchini S, Weverling GJ, Pariani E, Amendola A, Fabiano V, Pivetti V, Zanetti A, Zuccotti GV.
Source
Pediatric Clinic 1, Department of Pathophysiology and Transplantation, Universit? degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Commenda 9, 20122 Milan, Italy. Electronic address: susanna.esposito@unimi.it.
Abstract
This study evaluated the immunogenicity, safety and tolerability of a single 0.5mL dose of the seasonal virosomal subunit influenza vaccine (Inflexal V, Crucell, Switzerland) in 205 healthy, unprimed children aged at least 6 to <36 months, evaluated at four weeks post-vaccination and seven months from baseline. Of the enrolled children, 102 received one single 0.5mL dose and 103 received the standard two 0.25mL doses given four weeks apart. Both treatments evoked an immune response that satisfied the EMA/CHMP criteria for yearly vaccine licensing for all three vaccine strains. Exploratory analyses revealed no differences between the groups at four weeks post-vaccination. Furthermore, immunogenicity was maintained seven months after the first vaccination after both the 0.5mL and standard two 0.25mL doses. Adverse events were comparable between groups and were as expected according to the safety profile of the vaccine; overall, the vaccine was well tolerated. Our results show that a single 0.5mL dose effectively and safely provided long-term immunogenicity to all three influenza strains in unprimed children aged at least 6 to <36 months.
Copyright ? 2012. Published by Elsevier Ltd.
PMID:
23059357
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23059357